# Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Source: https://onco.cc/trials/nct06117774/  
OnCo record `nct06117774` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.

## Summary

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) is a phase 3 interventional study registered as NCT06117774 by Amgen, with 404 participants enrolled, started 2024-02-20 and due to reach its primary completion in 2030-04-20. Interventions recorded: Tarlatamab, Placebo. Conditions listed: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06117774
- Phase: 3
- Setting: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Sponsor: Amgen
- Enrolled: 404

## Sources

- ClinicalTrials.gov NCT06117774: https://clinicaltrials.gov/study/NCT06117774

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06117774.json